...solid tumor and lymphoma, for “business reasons.” Merck gained MK-4621 via its 2017 acquisition of Rigontec GmbH...

...of the strongest immune responses by a virus in a tumor.” Vollmer was CSO at Rigontec GmbH...

...former CEO of Rigontec GmbH, will be STipe’s executive chairman. Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...

...Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria...
...two therapeutics companies, two medtechs and a diagnostics company. One, the acquisition of immuno-oncology company Rigontec GmbH...
...milestones. The upfront payment was nearly a 4x return on the €29.3 million ($32.7 million) Rigontec...

...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...

...its third life sciences fund included acquisitions of NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...front plus up to $975 million in milestones, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...

...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH...
...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...

...a company that targeted the RIG-I pathway, that developed RIG-I agonists for immuno-oncology. The company [Rigontec GmbH]...

...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH...
...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec...
...Ingelheim GmbH, Ingelheim, Germany Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) GlaxoSmithKline plc Merck & Co. Inc. Okairos AG Rigontec GmbH Aelin...

...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH...
...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec...
...BioCentury Extra, Dec. 11, 2017) . Mary Romeo Boehringer Ingelheim GmbH Flanders Institute for Biotechnology (VIB) Merck & Co. Inc. Rigontec GmbH Aelin...